S-1: a promising new oral fluoropyrimidine derivative
The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a wide range of solid tumors, particularly gastric, colorectal, and head and neck cancers. Whilst infusional 5-FU is associated with higher response rates and a favorable safety profile compared with the classical i.v. bolus administration, prolonged infusions can be inconvenient for the patients, and catheter-related problems are common complications. An oral 5-FU formulation would allow for sustained 5-FU plasma concentrations, mimicking the pharmacokinetics (PK) of a continuous infusion with the addition of convenience of administration. The oral administration of 5-FU itself is not feasible owing to the high activity of dihydropyrimidine dehydrogenase (DPD) in the gut wall, which causes rapid metabolism of the drug and results in decreased and erratic absorption of 5-FU and nonlinear PK. To bypass this problem, oral fluoropyrimidine derivatives were developed either in the form of 5-FU prodrugs (i.e., tegafur, doxifluridine or capecitabine), or as enzyme inhibitors (i.e., eniluracil) administered with 5-FU, or as both prodrugs and enzyme inhibitors (i.e., S-1, UFT or BOF-A2). This review focuses on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Phase II trials have demonstrated that S-1, as a single agent, is active for the treatment of gastric, colorectal, head and neck, breast, non-small cell lung, and pancreatic cancers. Phase III trials are currently underway in gastric cancer and these results are awaited to confirm the Phase II findings. Furthermore, the combination of S-1 with cisplatin (CDDP), irinotecan or docetaxel for the treatment of gastric cancer and with CDDP for non-small cell and pancreatic cancer is feasible and active. The activity observed with S-1 in the Phase II studies is at least equivalent to, if not better than, continuous i.v. and bolus 5-FU and the other oral fluoropyrimidines. Thus, we may finally be seeing the realization of oral treatments for the management of various solid tumors and could be on the brink of a new approach to treatment strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The vast majority of 5-FU is catabolized into inactive metabolites by dihydropyrimidine dehydrogenase (DPD) in the liver [97].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [97]
Citations
Cites
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926 · cited 2×
“2 months was reported for docetaxel/CDDP/5-FU (DCF) by the V325 Study Group [104] ; 10.”
BackgroundInfluentialKoizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847 · cited 2×
“Interestingly, it seems that the difference in dosage of S-1 might be attributed to the higher activity of cytochrome P-450 2A6 enzyme – which catalyzes the conversion of tegafur to 5-FU – in white than in Japanese people as well as larger body surface area in North American people, leading to higher serum concentrati…”
BackgroundFluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603 · cited 1×
“[2] reported 5-fluorouracil (5-FU) in 1957, pharmacokinetic and biochemical studies of 5-FU have been widely conducted to examine different means of reinforcing its efficacy and its regimen [3] .”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge11893 · Cited by 1,338
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 904
Fluorouracil: biochemistry and pharmacology.
Pinedo, H. M., & Peters, G. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1653 · Cited by 834 · cited 1×
“[2] reported 5-fluorouracil (5-FU) in 1957, pharmacokinetic and biochemical studies of 5-FU have been widely conducted to examine different means of reinforcing its efficacy and its regimen [3] .”
BackgroundLokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773 · cited 1×
“The use of continuous infusion of 5-FU using portable infusion pumps allowed prolonged cell exposure to the drug and abolished the problem with its low half-life (5 – 20 min) and resulted in higher clinical activity [6-9] .”
Background
Research works printed but not linked: 59
- Kubota, 2001, Gan To Kagaku Ryoho, 28, 433
- Benson, 1998, Oncology (Williston Park), 12, 28
- Houghton, 1979, Cancer Res, 39, 2406
- Unemi, 1971, Gan No Rinsho, 17, 731
- Lamont, 1999, Clin Cancer Res, 5, 2289
- Skipper, 1964, Cancer Chemother Rep, 35, 1
- Fraile, 1980, Cancer Res, 40, 2223
- Schilsky, 1998, Oncology (Williston Park), 12, 13
- Toide, 1977, Gann, 68, 553
- Fujii, 1978, Gann, 69, 763
- Shirasaka, 2000, Gan To Kagaku Ryoho, 27, 832
- Tatsumi, 1987, Jpn J Cancer Res, 78, 748
- Shirasaka, 2006, Gan To Kagaku Ryoho, 33, 4
- Shirasaka, 1993, Cancer Res, 53, 4004
- Kato, 2001, Anticancer Res, 21, 1705
- Cao, 1999, Clin Cancer Res, 5, 267
- Shirasaka, 1996, Cancer Res, 56, 2602
- Shirasaka, 1993, Proc Int Congr Chemother, 18, 927
- Fukushima, 1998, Int J Oncol, 13, 693
- Shirasaka, 1998, Gan To Kagaku Ryoho, 25, 371
- Taguchi, 1997, Gan To Kagaku Ryoho, 24, 2253
- Hirata, 1999, Clin Cancer Res, 5, 2000
- Hoff, 1999, Proc Am Soc Clin Oncol, 18, 665
- Hoff, 2003, Clin Cancer Res, 9, 134
- Tagishi, 1996, Proc Am Soc Clin Oncol, 15, 151
- Taguchi, 1998, Gan To Kagaku Ryoho, 25, 1035
- Sano, 2000, Proc Am Soc Clin Oncol, 19, 404
- 10.1054/bjoc.2001.2031 · doi:10.1054/bjoc.2001.2031 · Paper page
- Fujii, 1996, Proc Am Soc Clin Oncol, 15, 894
- Inuyama, 1998, Gan To Kagaku Ryoho, 25, 1151
- Inuyama, 2001, Gan To Kagaku Ryoho, 28, 1381
- Okada, 2002, Proc Am Soc Clin Oncol, 21, 171a
- Hayashi, 2002, Oncol Rep, 9, 1355
- Sawada, 2002, Proc Am Soc Clin Oncol, 21, 102b
- Horikoshi, 1996, Proc Am Soc Clin Oncol, 15, 466
- Miyamoto, 2000, Int J Oncol, 17, 653
- Yoshida, 2001, Gan To Kagaku Ryoho, 28, 1403
- Inaba, 2002, Gan To Kagaku Ryoho, 29, 239
- Osugi, 2002, Oncol Rep, 9, 811
- Moriwaki, 2003, Gan To Kagaku Ryoho, 30, 489
- Fujitani, 2003, Hepato-gastroenterology, 50, 889
- Kinoshita, 2005, Prog Proc Am Soc Clin Oncol, 23, 313
- Scanlon, 1983, Cancer Res, 43, 4211
- Shirasaka, 1999, Gan To Kagaku Ryoho, 26, 456
- Mizutani, 1999, Oncol Rep, 6, 979
- Nishiyama, 1999, Clin Cancer Res, 5, 2620
- Tsuji, 1999, Gan To Kagaku Ryoho, 26, 326
- Ohtsu, 2001, Proc Am Soc Clin Oncol, 20, 165a
- Kamata, 2001, Gan To Kagaku Ryoho, 28, 1419
- Tsujitani, 2003, Proc Am Soc Clin Oncol, 22, 1358
- Narahara, 2002, Proc Am Soc Clin Oncol, 21, 170a
- Komatsu, 2002, Proc Am Soc Clin Oncol, 21, 171a
- Yamashita, 2003, Proc Am Soc Clin Oncol, 22, 1428
- Yamada, 2003, Proc Am Soc Clin Oncol, 22, 1314
- Komatsu, 2003, Proc Am Soc Clin Oncol, 22, 1282
- Rino, 2006, Anticancer Res, 26, 1455
- Yoshida, 2003, Proc Am Soc Clin Oncol, 22, 1292
- Saif, 2008, JOP, 9, 226
- Kouwaki, 1998, Clin Cancer Res, 4, 2999
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 628
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., et al. (2010) · Cancers · doi:10.3390/cancers2031717 · Cited by 260
“It has been demonstrated that 80% to 85% of 5-FU is catabolized to inactive metabolites by dihydropyrimidine dehydrogenase (DPD), and only 1 to 3% of the original dose of 5-FU mediates the cytotoxic effects on tumor cells and normal tissues through anabolic actions [6], thereby inhibiting DNA synthesis and RNA process…”
BackgroundOhtake, Y., Sato, T., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Yamaguchi, M., Takami, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300884k · Cited by 174
Metadata
- Authors
- Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Yale University (US)
- ORCID
- Saif, Muhammad Wasif
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2009-03
- Volume
- 18
- Issue
- 3
- Pages
- 335-348
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2168388707
- Cited by
- 101
- References
- 100
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 10 · 2023: 1 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 7 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 10
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- S-1, oral fluoropyrimidine, tegafur, 5-fluorouracil prodrug, dihydropyrimidine dehydrogenase inhibition, potassium oxonate, gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, combination chemotherapy
- MeSH terms
- Administration, Oral, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Drug Combinations, Drug Evaluation, Preclinical, Tegafur, Humans, Neoplasms, Oxonic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: S-1: a promising new oral fluoropyrimidine derivative. https://app.cochat.ai/papers/10.1517/13543780902729412
- The paper
- Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009). S-1: a promising new oral fluoropyrimidine derivative. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780902729412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.